

REMARKS

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks herein, is respectfully requested. Claims 1 and 50-53 are amended, and claims 56-57 are added; as a result, claims 1-31 and 44-57 are pending in this application.

Support for the amendments to claims 1 and 50-53, is found, for instance, at page 13, lines 19-25, page 19, lines 24-28, and page 20, lines 3-5 and 20-22 of the specification. Support for new claims 56 and 57 is found, for instance, in the example in the specification.

The 35 U.S.C. § 112, First Paragraph, Rejections

The Examiner rejected claims 1, 8-9, 15-19, 23, 25, and 44-55 under 35 U.S.C. § 112, first paragraph, as lacking adequate written description. Specifically, the Examiner alleges that the specification teaches the structure of only a single representative species of SEQ ID Nos:2, 3 and 4, and fails to describe any other representative species by any identifying characteristics or properties other than the functionality of hybridizing to SEQ ID NO:2, 3 or 4 and to fails describe polypeptides [*sic*] having at least 80%, 85%, 90%, 95% or 97% sequence identity to SEQ ID NO:2, 3 or 4. The Examiner also asserts that there is no support for the primers or probe consisting of 15 to 40 nucleotides which include SEQ ID NO:2, 3 or 4. The Examiner also rejected claims 1, 8-9, 15-19, 23, 25, and 44-55 under 35 U.S.C. § 112, first paragraph, as containing new matter. In particular, the Examiner alleges that there is no support for probes or primers having about 15 to 40 nucleotides with at least 80% identity to SEQ ID NO:2, 3,or 4 or the complement thereof that hybridizes to SEQ ID NO:2, 3, or 4. These rejections are respectfully traversed.

The Examiner is respectfully reminded that Applicant need not teach what is well known to the art. *vanA* sequences, including *vanA*-specific probes and primers, were well known to the art, as were amplification and hybridization assays to detect those and other sequences (see Petrich et al., Mol. Cell Probes, 13:275 (1999) and U.S. Patent No. 6,274,316; both of record, as well as the Table of Contents for Diagnostic Molecular Microbiology: Principles and Applications, Pershing, ed., American Society of Microbiology, 1993 (a copy is enclosed herewith)).

Moreover, Applicant's specification clearly identifies the nucleotide sequence corresponding to nucleotides 870 to 896, 851 to 868 and 898 to 917 of *vanA* (see Figure 1 and SEQ ID NOS. 2-4).

The Examiner cannot reasonably contend that the recitation of a primer or probe that forms a hybrid with, and has at least 80% nucleic acid sequence identity to, a particular nucleic acid structure does not convey a common structure or function. Hybrid formation and percent nucleic acid sequence identity between two nucleic acid molecules *clearly* convey a common structure (see, for example, the Table of Contents for Diagnostic Molecular Microbiology: Principles and Applications, Pershing, ed., American Society of Microbiology, 1993; The Polymerase Chain Reaction, Mullis et al., eds., Birkhauser, 1994 (copy enclosed), and Molecular Cloning: A Laboratory Manual, Sambrook et al., eds., Cold Spring Harbor Press, 2001 (copy enclosed)).

The Examiner also cannot reasonably contend that the skilled artisan cannot envision the detailed structure of nucleic acid sequences with at least 80% nucleic acid sequence identity to SEQ ID NO:2, 3 or 4. For instance, SEQ ID NO:2 has 18 nucleotides, SEQ ID NO:3 has 27 nucleotides, and SEQ ID NO:4 has 20 nucleotides. A sequence with 3 nucleotide substitutions relative to SEQ ID NO:2 has 83% identity thereto, a sequence with 6 nucleotide substitutions relative to SEQ ID NO:3 has 81% identity thereto, and a sequence with 4 nucleotide substitutions relative to SEQ ID NO:4 has 80% identity thereto.

Moreover specifically, SEQ ID NO:2 corresponds to CCGGTGGCAGCTACGTTT (18 nucleotides). 80% of 18 is 14.4. Therefore, probes within the scope of invention include those with up to 3 nucleotide substitutions in SEQ ID NO:2. The following represents a set of variants of SEQ ID NO:2 with a single substitution (indicated by underlining):

CGGGTGGCAGCTACGTTT, CAGGTGGCAGCTACGTTT, and

CTGGTGGCAGCTACGTTT. The following represents a set of variants of SEQ ID NO:2 with two substitutions (indicated by underlining): CGGGTGGCAGCTAGGTTT, CAGGTGGCAGCTAAGTTT, and CTGGTGGCAGCTATGTTT, and the following represents a set of variants of SEQ ID NO:2 with three substitutions (indicated by underlining): CGGGGGGCAGCTAGGTTT, CAGGAGGCAGCTAAGTTT, and CTGGGGCAGCTATGTTT.

Given that the Example in the specification discloses the use of SEQ ID Nos. 2-4 in a method to detect *vanA* sequences in a sample, and that the specification discloses that sequences

with close structural relatedness to SEQ ID Nos. 2-4, i.e., those with at least 80% nucleic acid sequence identity to the 18 nucleotides corresponding to SEQ ID NO:2, the 27 nucleotides corresponding to SEQ ID NO:3, and the 20 nucleotides corresponding to SEQ ID NO:4, are useful in the claimed methods, one of skill in the art would recognize that Applicant was in possession of the claimed invention.

It is unclear to Applicant why claims 54-55 do not satisfy the written description requirement, as they are directed to primers and probes with a specific sequence.

The fundamental inquiry with regard to new matter is whether the material added by amendment was inherently contained in the original application. *Litton Sys., Inc. v. Whirlpool Corp.*, 728 F.2d 1423, 1438, 221 U.S.P.Q. 97, 106 (Fed. Cir. 1984). The issue is not whether a specific new word of a claim was used in the specification as filed but whether the concept expressed by the word was present. *In re Anderson*, 471 F.2d 1237, 176 U.S.P.Q. 331 (C.C.P.A. 1973).

As filed, claim 1 recited that the *vanA*-specific oligonucleotide probe comprises sequences which include sequences substantially corresponding to nucleotides 870 to 896 of the *vanA* gene, the complement thereof, or a portion thereof, sequences substantially corresponding to nucleotides 851 to 868 of the *vanA* gene, the complement thereof, or a portion thereof, or sequences substantially corresponding to nucleotides 898 to 917 of the *vanA* gene, the complement thereof, or a portion thereof.

Claim 32 (as filed) is directed to an oligonucleotide composition comprising a first oligonucleotide comprising sequences substantially corresponding to nucleotides 870 to 896 of the *vanA* gene, the complement thereof, or a portion thereof, an oligonucleotide comprising sequences substantially corresponding to nucleotides 851 to 868 of the *vanA* gene the complement thereof, or a portion thereof, an oligonucleotide comprising sequences substantially corresponding to nucleotides 898 to 917 of the *vanA* gene, the complement thereof, or a portion thereof, or a combination thereof, wherein the oligonucleotide hybridizes under stringent hybridization conditions to *vanA* DNA. Claim 34 (as filed) depends on claim 32, and is directed to at least one oligonucleotide that has the length and sequence of any of SEQ ID NOs:2-4.

Pages 10 and 11 of the specification disclose that:

An "oligonucleotide" is a polynucleotide having two or more nucleotide subunits covalently joined together.

A "primer" is a single-stranded polyoligonucleotide that combines with a complementary single-stranded target to form a double-stranded hybrid, which primer in the presence of a polymerase and appropriate reagents and conditions, results in nucleic acid synthesis.

A "probe" is a single-stranded polynucleotide that combines with a complementary single-stranded target polynucleotide to form a double-stranded hybrid.

Page 6 of the specification discloses:

In one embodiment, the oligonucleotides of the invention include sequences substantially corresponding to nucleotides 851 to 868 of the vanA gene (SEQ ID NO:2; an exemplary vanA gene has SEQ ID NO:1 from *E. faecium* pIP816 gi 43335, also see Figure 1, Accession No. X56895 which corresponds to SEQ ID NO:11), or the complement thereof, or a portion thereof; sequences substantially corresponding to nucleotides 870 to 896 of the vanA gene (SEQ ID NO:3), the complement thereof, or a portion thereof; sequences substantially corresponding to nucleotides 898 to 917 of the vanA gene (SEQ ID NO:4), the complement thereof, or a portion thereof (emphasis added).

The Example discloses the use of primers having SEQ ID Nos. 2 and 4 to amplify vanA-specific sequences in a sample and a probe having SEQ ID NO:3 to detect vanA-specific sequences in a sample.

In the Amendment filed on May 30, 2007, Applicant indicated that support for the amendments to claim 1 is found, for instance, at page 13, lines 19-25, page 19, line 24-page 20, line 2, and page 20, lines 3-5 and 20-22 of the specification. Page 13 discloses that:

One skilled in the art will understand that probes or primers that substantially correspond to a reference sequence or region can vary from that reference sequence or region and still hybridize to the same target nucleic acid sequence. Probes of the present invention substantially correspond to a nucleic acid sequence or region if the percentage of identical bases or the percentage of perfectly complementary bases between the probe and its target sequence is from 100% to 80% or from 0 base mismatches in a 10 nucleotide target sequence to 2 bases mismatched in a 10 nucleotide target sequence. In one embodiment, the percentage is from 100% to 85%. In another embodiment this percentage is from 90% to 100%; and in yet other embodiments, this percentage is from 95% to 100% (emphasis added).

Page 19 discloses that:

Preferred methods for detecting the presence of the vanA or vanB gene, include the step of contacting a test sample with at least two oligonucleotide primers under conditions that

preferentially amplify *vanA* and/or *vanB* sequences....While oligonucleotides probes of different lengths and base composition may be used for detecting the *vanA* gene or the *vanB* gene, preferred oligonucleotides have lengths from 15 up to 40 nucleotides and are sufficiently homologous to the target nucleic acid to permit amplification of a *vanA* or *vanB* template and/or hybridization to such a template under high stringency conditions (emphasis added).

Page 19 also discloses that:

[T]he specific sequences described herein also may be provided in a nucleic acid cloning vector or transcript or other longer nucleic acid and still can be used for amplifying or detecting the *vanA* gene or the *vanB* gene, i.e., the probes may include sequences unrelated to the *vanA* or *vanB* gene, for instance at the 5' end, the 3' end, or both the 5' and 3' ends. Likewise, primers may include sequences unrelated to the *vanA* gene and/or the *vanB* gene, e.g., at the 5' end (emphasis added).

Page 20 discloses that:

Preferred primers and probes have sequences of up to 40 nucleotides in length and preferably have at least 17 contiguous nucleotides corresponding to sequences in the *vanA* gene or the *vanB* gene, or the complement thereof... Preferably, the probes specifically hybridize to *vanA* or *vanB* DNA only under conditions of high stringency. Under these conditions only highly complementary nucleic acid hybrids will form (i.e., those having at least 14 out of 17 bases in a contiguous series of bases being complementary). Hybrids will not form in the absence of a sufficient degree of complementarity (emphasis added).

Thus, the specification clearly provides support for the recited probes and primers.

Accordingly, withdrawal of the § 112, first paragraph, rejections is respectfully requested.

The 35 U.S.C. § 112, Second Paragraph, Rejections

The Examiner rejected claims 1, 8-9, 15-19, 23, 25, and 44-55 under 35 U.S.C. § 112, second paragraph, as being indefinite. In particular, the Examiner asserts that 1) claims 1 and 50-53 are unclear, as claims 1 and 50-53 recite the broad limitation of having 15 to 40 nucleotides, yet SEQ ID NOs:2, 3 and 4 do not have 40 nucleotides (the sequences have 18, 27 and 20 nucleotides, respectively), and the claims and specification fail to disclose what the other nucleotides are; 2) the term "hybridizes" in the claims is a relative term which renders the claims

indefinite; and 3) the phrase "one which under the same conditions hybridizes" in claim 1 is a relative phrase which renders the claims indefinite. These rejections, as they may be maintained with respect to the pending claims, are respectfully traversed.

The claims no longer recite "one which under the same conditions hybridizes", thereby obviating the § 112(2) rejection thereof.

It is Applicant's position that the metes and bounds of the recited primers and probe are clear. That is, the probe is a *vanA*-specific oligonucleotide that forms a hybrid with *vanA* nucleic acid in a sample. The probe consists of 15 to 40 nucleotides and has a sequence with at least 80% nucleic acid sequence identity to SEQ ID NO:3 or the complement of SEQ ID NO:3. The probe is one which forms a hybrid with SEQ ID NO:3 or its complement. Thus, the probe is of a particular length and has sequence homology to SEQ ID NO:3 or its complement.

The two primers are oligonucleotides that amplify *vanA* nucleic acid. The primers consist 15 to 40 nucleotides. One (the first) primer has a sequence with at least 80% nucleic acid sequence identity to SEQ ID NO:2, and the other (the second) primer has a sequence with at least 80% nucleic acid sequence identity to SEQ ID NO:4. The first primer forms a hybrid with the complement of SEQ ID NO:2, and the second primer forms a hybrid with the complement of SEQ ID NO:4. Hence, the primers are of a particular length and have sequence homology to SEQ ID NO:2 or SEQ ID NO:4.

For instance, a nucleic acid sequence which consists of 15 contiguous nucleotides of SEQ ID NO:2 (SEQ ID NO:2 has 18 nucleotides) has a sequence with 15 nucleotides having 100% nucleic acid sequence identity to SEQ ID NO:2; a nucleic acid sequence which consists of 15 nucleotides, 14 of which are identical in sequence to those in SEQ ID NO:2 and one of which is different, has a sequence with 15 nucleotides having at least 80% nucleic acid sequence identity to SEQ ID NO:2; and a nucleic acid sequence which consists of 40 nucleotides, 15 of which are identical in sequences to those in SEQ ID NO:2, has a sequence with 15 nucleotides having 100% nucleic acid sequence identity to SEQ ID NO:2.

Moreover, one of skill in the art understands that sequences other than those needed for specificity of a probe or primer may be included with the probe or primer, e.g., a restriction enzyme site may be included in a primer sequence to facilitate cloning of sequences amplified with the primer. For example at page 19 of the specification, it is disclosed that:

the specific sequences described herein also may be provided in a nucleic acid cloning vector or transcript or other longer nucleic acid and still can be used for amplifying or detecting the *vanA* gene or the *vanB* gene, i.e., the probes may include sequences unrelated to the *vanA* or *vanB* gene, for instance at the 5' end, the 3' end, or both the 5' and 3' ends. Likewise, primers may include sequences unrelated to the *vanA* gene and/or the *vanB* gene, e.g., at the 5' end.

Therefore, the metes and bounds of the recited probe and primers is clear.

It is Applicant's position that one of skill in the art would understand the metes and bounds of the term "hybridizes" as it is conventionally used in the art. See, e.g., Petrich et al. *supra*, and U.S. Patent No. 6,274,316, *supra*, which disclose primers or probes that hybridize to *vanA* sequences in a biological sample. It is also Applicant's position that the selection of amplification and/or hybridization conditions specific for vanA sequences is conventional in the art. See, for instance, Petrich et al., *supra*, Patel et al., "Multiplex PCR Detection of *vanA*, *vanB*, *vanC-1*, and *vanC-2/3* Genes in Enterococci", *J. Clin. Microbiology*, 35: 703 (1997); Petrich et al., "Effect of Routine Use of a Multiplex PCR for Detection of *vanA*- and *vanB*- Mediated Enterococcal Resistance on Accuracy, Costs and Earlier Reporting", Diagnostic Microbiology and Infectious Disease, 41:215 (2001); and Satake et al., "Detection of Vancomycin-Resistant Enterococci in Fecal Samples by PCR", *J. Clin. Microbiology*, 35:2325 (1997); all of record.

Moreover, one of skill in the art is aware that more than one set of conditions can result in the specific hybridization of two nucleic acid sequences.

Even if, assuming for the sake of argument, the metes and bounds of the term "hybridizes" was not readily recognizable to one skilled in the art, the specification discloses particular conditions at page 20 (for amplification reactions with primers) and pages 24-25 (for probes). Thus, the scope of the claims would be clear to a person of skilled in the art, particularly when read in light of the specification.

Nevertheless, to advance the application, "hybridizes" has been deleted from claim 1.

Accordingly, withdrawal of the § 112, second paragraph, rejections is respectfully requested.

CONCLUSION

Applicant respectfully submits that the claims are in condition for allowance, and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney at (612) 373-6959 to facilitate prosecution of this application.


If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

May 5, 2008


By 
Janet E. Imbretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Mail Stop Amendment, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 5 day of May 2008.

CANDIS BUENDING

Name

Signature



Diagnostic Molecular Microbiology

PRINCIPLES AND APPLICATIONS

Edited by

David H. Persing, M.D., Ph.D.

Section of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota

Thomas F. Smith, Ph.D.

Section of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota

Fred C. Tenover, Ph.D.

National Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia

Thomas J. White, Ph.D.

Roche Molecular Systems, Alameda, California

AMERICAN SOCIETY FOR MICROBIOLOGY
WASHINGTON, D.C.

Copyright © 1993 Mayo Foundation
Rochester, MN 55905

Library of Congress Cataloging-in-Publication Data

Diagnostic molecular microbiology : principles and applications / edited by

David H. Persing . . . [et al.]

p. cm.

Includes index.

ISBN 1-55581-056-X

1. DNA probes—Diagnostic use. 2. Diagnostic microbiology—Technique. 3. Nucleic acid hybridization. 4. Communicable diseases—Diagnosis—Laboratory manuals. I. Persing, David H.

QR69.D4D5 1993

616.9'047583—dc20

92-38523

CIP

*All Rights Reserved
Printed in the United States of America*

This book was coedited and chapter 1 was cowritten by Fred C. Tenover in his private capacity. No official support or endorsement by CDC is intended or should be inferred.

Cover illustration by Tomo Narashima

Contents

Contributors	ix
Foreword. <i>Albert Balows</i>	xix
Preface. <i>David H. Persing</i>	xxi

Part I. Principles of Diagnostic Molecular Microbiology

1. Nucleic Acid Probes for Detection and Identification of Infectious Agents. <i>Fred C. Tenover and Elizabeth R. Unger</i>	3
2. Molecular Typing Methods. <i>Bala Swaminathan and Ghassan M. Matar</i>	26
3. In Vitro Nucleic Acid Amplification Techniques. <i>David H. Persing</i>	51
4. Target Selection and Optimization of Amplification Reactions. <i>David H. Persing</i>	88
5. Amplification Product Inactivation Methods. <i>David H. Persing and George D. Cirino</i>	105
6. Sample Preparation Methods. <i>Larry Greenfield and Thomas J. White</i>	122
7. Amplification Product Detection Methods. <i>Thomas J. White</i>	138
8. Laboratory Design and Work Flow. <i>Bruce J. McCreedy and Thomas H. Callaway</i>	149
9. Quality Control of Polymerase Chain Reaction. <i>Elizabeth A. Dragon, Joanne P. Spadoro, and Roberta Madej</i>	160

Part II. Applications of Diagnostic Molecular Microbiology

SECTION 1. Bacterial Pathogens

1.1 Genotypic Identification and Detection of Mycobacteria—Facing Novel and Uncultured Pathogens. <i>Philip Kirschner, Albrecht Meier, and Erik C. Böttger</i>	173
1.2 PCR Detection of <i>Mycobacterium tuberculosis</i> . <i>Kathleen D. Eisenach, M. Donald Cave, and Jack T. Crawford</i>	191
1.3 PCR Detection of <i>Rickettsia rickettsii</i> and <i>Ehrlichia chaffeensis</i> . <i>Burt E. Anderson</i>	197
1.4 PCR Detection of <i>Borrelia burgdorferi</i> . <i>Paul N. Rys</i>	203
1.5 Rapid Ribosequencing for the Detection and Classification of Tick-Borne <i>Borrelia burgdorferi</i> and Related Species. <i>Ulf B. Göbel, Barbara Graf, and Thomas Adam</i>	211
1.6 PCR Detection of <i>Yersinia pestis</i> in Fleas. <i>J. Hirnebusch and Tom G. Schwän</i>	218
1.7 PCR Detection of <i>Treponema pallidum</i> . <i>Justin D. Radolf</i>	224
1.8 Molecular Detection of <i>Treponema pallidum</i> via a 16S Target. <i>Jeffrey S. Sartin</i>	230
1.9 PCR Detection of <i>Chlamydia trachomatis</i> . <i>Linda D. Bobo</i>	235

1.10	3SR Detection of <i>Chlamydia trachomatis</i> . <i>Paul V. Haydock and Sharon A. Kochik</i>	242
1.11	PCR Detection of <i>Chlamydia pneumoniae</i> . <i>Lee Ann Campbell</i>	247
1.12	PCR Detection of <i>Mycoplasma pneumoniae</i> . <i>Maurice Garret and Jacques Bonnet</i>	253
1.13	Rapid and Sensitive PCR Method for Identification of <i>Mycoplasma</i> Species in Tissue Culture. <i>Jolene G. Wong-Lee and Michael Lovett</i>	257
1.14	PCR Detection of <i>Legionella pneumophila</i> and <i>L. dumoffii</i> in Water. <i>Jeffery S. Loutit and Lucy S. Tompkins</i>	261
1.15	PCR Detection of Toxin Genes in Strains of <i>Vibrio cholerae</i> O1. <i>Ørjan Olsvik, Tanja Popovic, and Patricia I. Fields</i>	266
1.16	PCR Detection of Heat-Stable, Heat-Labile, and Shiga-Like Toxin Genes in <i>Escherichia coli</i> . <i>Ørjan Olsvik and Nancy A. Strockbine</i>	271
1.17	PCR Detection of <i>Shigella</i> Species and Enteroinvasive <i>Escherichia coli</i> . <i>Gary K. Schoolnik</i>	277
1.18	PCR Detection of <i>Helicobacter pylori</i> . <i>Joan L. Valentine</i>	282
1.19	PCR Detection of Toxigenic <i>Clostridium difficile</i> . <i>Paul H. Gumerlock, Yajarayma J. Tang, and Joseph Silva, Jr.</i>	288
1.20	PCR Detection of Genes for Enterotoxins, Exfoliative Toxins, and Toxic Shock Syndrome Toxin-1 in <i>Staphylococcus aureus</i> . <i>W. M. Johnson and S. D. Tyler</i>	294
1.21	PCR Detection of Bacteria Found in Cerebrospinal Fluid. <i>Diane U. Leong and Kay S. Greisen</i>	300

SECTION 2. Viral Pathogens

2.1	PCR Detection of Human Immunodeficiency Virus Type 1 Proviral DNA Sequences. <i>Shirley Kwok and John J. Sninsky</i>	309
2.2	PCR Detection of Human T-Cell Lymphotropic Virus Type I. <i>Moses Rodriguez, Naraporn Prayoonwiwat, and Larry R. Pease</i>	316
2.3	PCR Detection of Hepatitis B Virus. <i>Osamu Yokosuka, Masami Tagawa, and Masao Omata</i>	322
2.4	Reverse Transcriptase-PCR for Hepatitis C Virus RNA. <i>Judith C. Wilber, Pamela J. Johnson, and Mickey S. Urdea</i>	327
2.5	PCR Detection of Herpes Simplex Virus DNA Sequences in Cerebrospinal Fluid. <i>Mark J. Espy, Jaber Aslanzadeh, and Thomas F. Smith</i>	332
2.6	PCR Detection of Herpes Simplex Virus. <i>Richard W. Cone and Ann C. Hobson</i>	337
2.7	PCR Detection and Typing of Epstein-Barr Virus. <i>Amalio Telenti</i>	344
2.8	PCR Detection of Cytomegalovirus DNA Sequences in Clinical Specimens. <i>Mark J. Espy and Thomas F. Smith</i>	350
2.9	PCR Detection of Varicella-Zoster Virus. <i>Elisabeth Puchhammer-Stöckl</i>	356
2.10	PCR Detection of JC Virus. <i>Allen J. Aksamit, Jr.</i>	361
2.11	PCR Detection of Parvovirus B19. <i>Jonathan P. Clewley</i>	367

Contents

vii

2.12	PCR Detection and Differentiation of Influenza Virus A, B, and C Strains. <i>Wandong Zhang and David H. Evans</i>	374
2.13	PCR Detection of Rotavirus. <i>Vera Gouvea</i>	383
2.14	PCR Detection of Human Adenoviruses. <i>Michael McDonough, Olen Kew, and John Hierholzer</i>	389
2.15	PCR Detection of Rubella Virus. <i>Clark B. Inderlied and Kevin A. Nash</i>	394
2.16	PCR Detection of the Human Enteroviruses. <i>José R. Romero and Harley A. Rotbart</i>	401
2.17	PCR Detection of Genital Human Papillomavirus. <i>Heidi M. Bauer and M. Michele Manos</i>	407
2.18	Rapid Amplification of Human Papillomavirus Type 16 and 18 E6 and E7 mRNA by 3SR. <i>Janice T. Brown and Alan T. Wortman</i>	414

SECTION 3. Fungal Pathogens

3.1	A Model PCR/Probe System for the Identification of Fungal Pathogens. <i>Barbara H. Bowman</i>	423
3.2	PCR Identification of <i>Cryptococcus neoformans</i> . <i>T. G. Mitchell, E. Z. Freedman, W. Meyer, T. J. White, and J. W. Taylor</i>	431
3.3	PCR Detection of <i>Pneumocystis carinii</i> : Diagnosis and Therapeutic Monitoring. <i>Yoshikazu Nakamura</i>	437

SECTION 4. Parasitic Pathogens

4.1	PCR Detection of <i>Trypanosoma cruzi</i> , African Trypanosomes, and <i>Leishmania</i> Species. <i>Louis V. Kirchhoff and John E. Donelson</i>	443
4.2	PCR Detection of <i>Leishmania braziliensis</i> . <i>Jorge Arévalo, Rocio Inga, and Martín López</i>	456
4.3	PCR Detection of <i>Plasmodium</i> Species in Blood and Mosquitoes. <i>Konstantinos Mathiopoulos, Madama Bouaré, Glenn McConkey, and Thomas McCutchan</i>	462
4.4	PCR Detection of Pathogenic <i>Entamoeba histolytica</i> and Differentiation from Other Intestinal Protozoa by Riboprinting. <i>C. Graham Clark</i>	468
4.5	PCR Detection of <i>Babesia microti</i> . <i>David H. Persing</i>	475
4.6	PCR Detection of <i>Giardia lamblia</i> . <i>Judith B. Weiss</i>	480

SECTION 5. Novel Organisms

5.1	Universal Bacterial 16S rDNA Amplification and Sequencing. <i>David A. Relman</i>	489
5.2	PCR-Based Detection of the Uncultured <i>Bacillus</i> of Whipple's Disease. <i>David A. Relman</i>	496
5.3	Detection of Human Herpesvirus 6 and Human Herpesvirus 7 by PCR Amplification. <i>Mary E. Klotman, Paolo Lusso, David Bacchus, Mario Corbellino, Ruth F. Jarrett, and Zwi N. Berneman</i>	501

- 5.4 PCR Detection of *Mycoplasma fermentans* Infection in Blood and Urine. *Richard Y.-H. Wang and Shyh-Ching Lo* 511

SECTION 6. Antimicrobial Resistance Loci

- 6.1 Detection of Rifampin Resistance Mutations in *Mycobacterium tuberculosis* and *M. leprae*. *Paul Imboden, Stewart Cole, Thomas Bodmer, and Amalio Telenti* 519
- 6.2 PCR Detection of Human Immunodeficiency Virus Drug Resistance Mutations. *Brendan A. Larder and Charles A. B. Boucher* 527
- 6.3 PCR Detection of *erm* Erythromycin Resistance Genes by Using Degenerate Oligonucleotide Primers. *Michel Arthur, Catherine Molinas, and Claude Mabilat* 534
- 6.4 PCR Identification of Methicillin-Resistant *Staphylococcus aureus*. *Kazuhisa Murakami and Wakio Minamide* 539
- 6.5 PCR Detection of Penicillinase-Producing *Neisseria gonorrhoeae*. *Jean-Luc Simard and Paul H. Roy* 543
- 6.6 PCR Detection of Genes Coding for Aminoglycoside-Modifying Enzymes. *Jos A. M. van de Klundert and John S. Vliegenthart* 547
- 6.7 PCR Detection and Identification of Genes for Extended-Spectrum β -Lactamases. *Claude Mabilat and Sylvie Goussard* 553

SECTION 7. Molecular Typing Methods

- 7.1 Application of Pulsed-Field Gel Electrophoresis to Molecular Epidemiology. *Joel N. Maslow, Alexander M. Slutsky, and Robert D. Arbeit* 563
- 7.2 Ribotyping in Molecular Epidemiology. *Tanja Popovic, Cheryl A. Bopp, Ørjan Olsvik, and Julia A. Kiehlbauch* 573
- 7.3 Chemiluminescent Ribotyping. *Cynthia A. Gustafero* 584
- 7.4 PCR Analysis of Integrons. *Céline Lévesque and Paul H. Roy* 590
- 7.5 Characterization of Pathogenic Microorganisms by Genomic Fingerprinting Using Arbitrarily Primed PCR. *John Welsh and Michael McClelland* 595

SECTION 8. Methods

- 8.1 Simple and Rapid Sample Preparation Methods for Whole Blood and Blood Plasma. *Lily Lin, Yu Gong, Ken Metchette, George D. Cimino, John E. Hearst, and Stephen T. Isaacs* 605
- 8.2 Universal Bacterial DNA Isolation Procedure. *L. M. Graves and B. Swaminathan* 617
- Appendix. Suggested Materials. *Paul N. Rys* 623
- Index 629

The Polymerase Chain Reaction

Kary B. Mullis
François Ferré
Richard A. Gibbs
Editors

Foreword by James D. Watson

With 112 Illustrations

Birkhäuser
Boston • Basel • Berlin

Kary B. Mullis
La Jolla, CA 92037
USA

François Ferré
The Immune Response Corporation
5935 Darwin Court
Carlsbad, CA 92008
USA

Richard A. Gibbs
Institute for Molecular Genetics
Baylor College of Medicine
One Baylor Plaza
Houston, TX 77030
USA

Printed on acid-free paper.

© 1994 Birkhäuser Boston
®
Birkhäuser

Copyright is not claimed for works of U.S. Government employees.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission of the copyright owner.

The use of general descriptive names, trademarks, etc., in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Permission to photocopy for internal or personal use, or the internal or personal use of specific clients, is granted by Birkhäuser Boston for libraries and other users registered with the Copyright Clearance Center (CCC), provided that the base fee of \$6.00 per copy, plus \$0.20 per page is paid directly to CCC, 21 Congress Street, Salem, MA 01970, USA. Special requests should be addressed directly to Birkhäuser Boston, 675 Massachusetts Avenue, Cambridge, MA 02193, USA.

ISBN 0-8176-3607-2 (hardcover) ISBN 0-8176-3750-8 (softcover)
ISBN 3-7643-3607-2 (hardcover) ISBN 3-7643-3750-8 (softcover)

Typeset by Sherman Typography, York, PA.
Printed and bound by The Maple Press Company, York, PA.
Printed in the United States of America.

9 8 7 6 5 4 3 2 1

Cover illustration: Based on a photograph taken by Kary Mullis in a museum in Cologne. "The mosaic had been taken from Italy by the Germans. I think it was from Pompeii. I saw a similar design still intact in its original location in Herculaneum but had no camera that day. Vesuvius covered both cities in 79 A.D. I would guess that the structure of DNA was probably worked out about two thousand years before Watson was born and therefore nineteen hundred and eighty-eight years before Crick. The Romans, however, seemed to think that atoms were square, and most likely the significance of the structure did escape their notice. Of course, this was long before Avery."

Contents

Foreword <i>James D. Watson</i>	v
--	---

Preface <i>Kary B. Mullis</i>	ix
--	----

Contributors	xix
--------------------	-----

PART ONE: METHODOLOGY

I. Basic Methodology

1. Manipulation of DNA by PCR <i>Kenshi Hayashi</i>	3
2. Cloning PCR Products <i>Michael A. Frohman</i>	14
3. Optimization of Multiplex PCRs <i>Jeffrey S. Chamberlain and Joel R. Chamberlain</i>	38
4. Preparation of Nucleic Acids for Archival Material <i>Darryl Shibata</i>	47
5. PCR Amplification of Viral DNA and Viral Host Cell mRNAs <i>in Situ</i> <i>Janet Embretson, Katherine Staskus, Ernest Retzel, Ashley T. Haase, and Peter Bitterman</i>	55

II. Quantitation

6. Quantitative PCR: An Overview <i>F. Ferré, A. Marchese, P. Pezzoli, S. Griffin, E. Buxton, and V. Boyer</i>	67
7. Quantification of DNAs by the Polymerase Chain Reaction Using an Internal Control <i>Donald M. Coen</i>	89

8. RT-PCR and mRNA Quantitation <i>Jamel Chelly and Axel Kahn</i>	97
9. Analysis of Human T-Cell Repertoires by PCR <i>Dominic G. Spinella and James M. Robertson</i>	110
III. Nonisotopic Detection	
10. Ultrasensitive Nonradioactive Detection of PCR Reactions: An Overview <i>Richard H. Tullis</i>	123
11. Fluorescent Detection Methods for PCR Analysis <i>Michael J. Heller</i>	134
12. Enzyme-Labeled Oligonucleotides <i>Eugene Tu and Edward Jablonski</i>	142
13. Application of the Hybridization Protection Assay (HPA) to PCR <i>Norman C. Nelson and Sherrol H. McDonough</i>	151
IV. Instrumentation	
14. PCR Instrumentation: Where Do We Stand? <i>Christian C. Oste</i>	165
15. Rapid Cycle DNA Amplification <i>Carl T. Wittwer, Gudrun B. Reed, and Kirk M. Ririe</i>	174
16. Automating the PCR Process <i>H.R. Garner</i>	182
V. Sequencing	
17. PCR and DNA Sequencing <i>Bjorn Andersson and Richard A. Gibbs</i>	201
18. Phage Promoter-Based Methods for Sequencing and Screening for Mutations <i>Steve S. Sommer and Erica L. Vielhaber</i>	214
19. Capture PCR: An Efficient Method for Walking Along Chromosomal DNA and cDNA <i>André Rosenthal, Matthias Platzer, and D. Stephen Charnock-Jones</i>	222
PART TWO: APPLICATIONS	
I. General Applications	
20. <i>In Vitro</i> Evolution of Functional Nucleic Acids: High-Affinity RNA Ligands of the HIV-1 rev Protein <i>Craig Tuerk, Sheela MacDougal-Waugh, Gerald Z. Hertz, and Larry Gold</i> ...	233
21. The Application of PCR to Forensic Science <i>Bruce Budowle, Antti Sajantila, Manfred N. Hochmeister, and Catherine T. Comey</i>	244
22. Recreating the Past by PCR <i>Matthias Höss, Oliva Handt, and Svante Pääbo</i>	257
23. Nonbiological Applications <i>Gavin Dollinger</i>	265

II. Genetic Analysis

24. RT-PCR and Gene Expression
Didier Montarras, Christian Pinset, Jamel Chelly, and Axel Kahn 277
25. Fingerprinting Using Arbitrarily Primed PCR: Application to Genetic Mapping, Population Biology, Epidemiology, and Detection of Differentially Expressed RNAs
John Welsh and Michael McClelland 295
26. Genetics, Plants, and the Polymerase Chain Reaction
Bruno W.S. Sobral and Rhonda J. Honeycutt 304

III. Assessment of Therapy Effectiveness

27. PCR Assessment of the Efficacy of Therapy in Philadelphia Chromosome-Positive Leukemias
Stephen P. Hunger and Michael L. Cleary 323
28. The Detection of Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia Using Clone-Specific Probes Directed against V(D)J Junctional Sequences
Luc d'Auriol and François Sigaux 335
29. Assessment of Therapy Effectiveness: Infectious Disease
Salvatore J. Arrigo 344
30. Gene Therapy
Richard A. Morgan and W. French Anderson 357

IV. Diagnostics

31. PCR and Cancer Diagnostics: Detection and Characterization of Single Point Mutations in Oncogenes and Antioncogenes
Manuel Perucho 369
32. Clinical Applications of the Polymerase Chain Reaction
Belinda J.F. Rossiter and C. Thomas Caskey 395
33. Infectious Diseases
W. John Martin 406

PART THREE: PCR AND THE WORLD OF BUSINESS

34. PCR in the Marketplace
Ellen Daniell 421
35. PCR and Scientific Invention: The Trial of DuPont vs. Cetus
Kary B. Mullis 427
- Index 442

VOLUME 1

Molecular Cloning

A LABORATORY MANUAL

THIRD EDITION

www.MolecularCloning.com

Joseph Sambrook

PETER MACCALLUM CANCER INSTITUTE AND THE UNIVERSITY OF MELBOURNE, AUSTRALIA

David W. Russell

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DALLAS



COLD SPRING HARBOR LABORATORY PRESS
Cold Spring Harbor, New York

VOLUME 2

Molecular Cloning

A LABORATORY MANUAL

THIRD EDITION

www.MolecularCloning.com

Joseph Sambrook

PETER MACCALLUM CANCER INSTITUTE AND THE UNIVERSITY OF MELBOURNE, AUSTRALIA

David W. Russell

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DALLAS



COLD SPRING HARBOR LABORATORY PRESS
Cold Spring Harbor, New York

VOLUME 3

Molecular Cloning

A LABORATORY MANUAL

THIRD EDITION

www.MolecularCloning.com

Joseph Sambrook

PETER MACCALLUM CANCER INSTITUTE AND THE UNIVERSITY OF MELBOURNE, AUSTRALIA

David W. Russell

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DALLAS



COLD SPRING HARBOR LABORATORY PRESS
Cold Spring Harbor, New York

Molecular Cloning

A LABORATORY MANUAL

THIRD EDITION

©2001 by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
All rights reserved
Printed in the United States of America

Front cover (paperback): The gene encoding green fluorescent protein was cloned from *Aequorea victoria*, a jellyfish found in abundance in Puget Sound, Washington State. This picture of a 50-mm medusa was taken on color film by flash photography and shows light reflected from various morphological features of the animal. The small bright roundish blobs in the photograph are symbiotic amphipods living on or in the medusa. The bright ragged area in the center is the jellyfish's mouth.

Bioluminescence from *Aequorea* is emitted only from the margins of the medusae and cannot be seen in this image. Bioluminescence of *Aequorea*, as in most species of jellyfish, does not look like a soft overall glow, but occurs only at the rim of the bell and, given the right viewing conditions, would appear as a string of nearly microscopic fusiform green lights. The primary luminescence produced by *Aequorea* is actually bluish in color and is emitted by the protein aequorin. In a living jellyfish, light is emitted via the coupled green fluorescent protein, which causes the luminescence to appear green to the observer.

The figure and legend were kindly provided by Claudia Mills of the University of Washington, Friday Harbor. For further information, please see Mills, C.E. 1999–2000. Bioluminescence of *Aequorea*, a hydromedusa. Electronic Internet document available at <http://faculty.washington.edu/cemills/Aequorea.html>. Published by the author, web page established June 1999, last updated 23 August 2000.

Back cover (paperback): A portion of a human cDNA array hybridized with a red fluor-tagged experimental sample and a green fluor-tagged reference sample. Please see Appendix 10 for details. (Image provided by Vivek Mittal and Michael Wigler, Cold Spring Harbor Laboratory.)

Library of Congress Cataloging-in-Publication Data

Sambrook, Joseph.

Molecular cloning : a laboratory manual / Joseph Sambrook, David W. Russell.-- 3rd ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 0-87969-576-5 (cloth) -- ISBN 0-87969-577-3 (pbk)

I. Molecular cloning--Laboratory manuals.

[DNLM: 1. Cloning, Molecular--Laboratory Manuals. QH 440.5 S187m 2001] I. Russell, David W. (David William), 1954-. II. Title.

QH442.2 .S26 2001

572.8--dc21

00-064380

10 9 8 7 6 5 4 3 2 1

People using the procedures in this manual do so at their own risk. Cold Spring Harbor Laboratory makes no representations or warranties with respect to the material set forth in this manual and has no liability in connection with the use of these materials.

All World Wide Web addresses are accurate to the best of our knowledge at the time of printing.

Certain experimental procedures in this manual may be the subject of national or local legislation or agency restrictions. Users of this manual are responsible for obtaining the relevant permissions, certificates, or licenses in these cases. Neither the authors of this manual nor Cold Spring Harbor Laboratory assume any responsibility for failure of a user to do so.

The polymerase chain reaction process and other techniques in this manual may be or are covered by certain patent and proprietary rights. Users of this manual are responsible for obtaining any licenses necessary to practice PCR and other techniques or to commercialize the results of such use. COLD SPRING HARBOR LABORATORY MAKES NO REPRESENTATION THAT USE OF THE INFORMATION IN THIS MANUAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cold Spring Harbor Laboratory Press, provided that the appropriate fee is paid directly to the Copyright Clearance Center (CCC). Write or call CCC at 222 Rosewood Drive, Danvers, MA 01923 (508-750-8400) for information about fees and regulations. Prior to photocopying items for educational classroom use, contact CCC at the above address. Additional information on CCC can be obtained at CCC Online at <http://www.copyright.com/>

All Cold Spring Harbor Laboratory Press publications may be ordered directly from Cold Spring Harbor Laboratory Press, 10 Skyline Drive, Plainview, New York 11803-2500. Phone: 1-800-843-4388 in Continental U.S. and Canada. All other locations: (516) 349-1930. FAX: (516) 349-1946. E-mail: cshlpress@cshl.org. For a complete catalog of all Cold Spring Harbor Laboratory Press publications, visit our World Wide Web Site <http://www.cshl.org/>

For orders from Europe, the Middle East, and Africa, British pound pricing is provided. Orders are fulfilled and shipped from Cold Spring Harbor Laboratory Press-Europe c/o Lavis Marketing, 73 Lime Walk, Headington, Oxford OX3 7AD, U.K. Phone: +44 (0) 1865 741541. FAX: +014 (0)1865 750079. E-mail: cshlpress.europe@cshl.org. World Wide Web Site: <http://www.cshlpress.co.uk>

Contents

Preface	xxi
Acknowledgments	xxiii
On-line Edition	xxv
Quotation Credits	xxvii

Volume 1

Chapter 1	
<u>Plasmids and Their Usefulness in Molecular Cloning</u>	1.1

INTRODUCTION

PROTOCOLS

Introduction to Preparation of Plasmid DNA by Alkaline Lysis with SDS (Protocols 1-3)	1.31
1 Preparation of Plasmid DNA by Alkaline Lysis with SDS: Minipreparation	1.32
2 Preparation of Plasmid DNA by Alkaline Lysis with SDS: Midipreparation	1.35
3 Preparation of Plasmid DNA by Alkaline Lysis with SDS: Maxipreparation	1.38
Introduction to Preparation of Plasmid DNA by Boiling Lysis (Protocols 4 and 5)	1.43
4 Preparation of Plasmid DNA by Small-scale Boiling Lysis	1.44
5 Preparation of Plasmid DNA by Large-scale Boiling Lysis	1.47
6 Preparation of Plasmid DNA: Toothpick Minipreparation	1.51
7 Preparation of Plasmid DNA by Lysis with SDS	1.55
8 Purification of Plasmid DNA by Precipitation with Polyethylene Glycol	1.59
9 Purification of Plasmid DNA by Chromatography	1.62
10 Purification of Closed Circular DNA by Equilibrium Centrifugation in CsCl-Ethidium Bromide Gradients: Continuous Gradients	1.65
11 Purification of Closed Circular DNA by Equilibrium Centrifugation in CsCl-Ethidium Bromide Gradients: Discontinuous Gradients	1.69
12 Removal of Ethidium Bromide from DNA by Extraction with Organic Solvents	1.72
13 Removal of Ethidium Bromide from DNA by Ion-exchange Chromatography	1.75
14 Removal of Small Fragments of Nucleic Acid from Preparations of Plasmid DNA by Centrifugation through NaCl	1.78
15 Removal of Small Fragments of Nucleic Acid from Preparations of Plasmid DNA by Chromatography through Sephadryl S-1000	1.80
16 Removal of Small Fragments of Nucleic Acid from Preparations of Plasmid DNA by Precipitation with Lithium Chloride	1.82
17 Directional Cloning into Plasmid Vectors	1.84

vi *Contents*

18	Attaching Adaptors to Protruding Termini	1.88
19	Blunt-ended Cloning into Plasmid Vectors	1.90
20	Dephosphorylation of Plasmid DNA	1.93
21	Addition of Synthetic Linkers to Blunt-ended DNA	1.98
22	Ligating Plasmid and Target DNAs in Low-melting-temperature Agarose	1.103
23	The Hanahan Method for Preparation and Transformation of Competent <i>E. coli</i> : High-efficiency Transformation	1.105
24	The Inoue Method for Preparation and Transformation of Competent <i>E. coli</i> : "Ultra-competent" Cells	1.112
25	Preparation and Transformation of Competent <i>E. coli</i> using Calcium Chloride	1.116
26	Transformation of <i>E. coli</i> by Electroporation	1.119
27	Screening Bacterial Colonies Using X-gal and IPTG: α -Complementation • Alternative Protocol: Direct Application of X-gal and IPTG to Agar Plates	1.123
28	Screening Bacterial Colonies by Hybridization: Small Numbers	1.125
29	Screening Bacterial Colonies by Hybridization: Intermediate Numbers • Alternative Protocol: Rapid lysis of Colonies and Binding of DNA to Nylon Filters	1.126
30	Screening Bacterial Colonies by Hybridization: Large Numbers	1.129
31	Lysing Colonies and Binding of DNA to Filters	1.131
32	Hybridization of Bacterial DNA on Filters	1.132
		1.135
		1.138
INFORMATION PANELS		
	Chloramphenicol	1.143
	Kanamycins	1.145
	pBR322	1.146
	Tetracycline	1.147
	Ampicillin and Carbenicillin	1.148
	X-gal	1.149
	α -Complementation	1.149
	Ethidium Bromide	1.150
	Condensing and Crowding Reagents	1.152
	Purification of Plasmid DNA by PEG Precipitation	1.152
	Lysozymes	1.153
	Polyethylene Glycol	1.154
	Cesium Chloride and Cesium Chloride Equilibrium Density Gradients	1.154
	DNA Ligases	1.157
	Adaptors	1.160
	Electroporation	1.162

Chapter 2
Bacteriophage λ and Its Vectors 2.1

INTRODUCTION**PROTOCOLS**

1	Plating Bacteriophage λ	2.25
	• Additional Protocol: Plaque-Assay of Bacteriophages That Express β -Galactosidase	2.30
	• Additional Protocol: Macroplaques	2.31

2	Picking Bacteriophage λ Plaques	2.32
3	Preparing Stocks of Bacteriophage λ by Plate Lysis and Elution	2.34
	• Alternative Protocol: Preparing Stocks of Bacteriophage λ by Plate Lysis and Scraping	2.37
4	Preparing Stocks of Bacteriophage λ by Small-scale Liquid Culture	2.38
5	Large-scale Growth of Bacteriophage λ: Infection at Low Multiplicity	2.40
	• Alternative Protocol: Large-scale Growth of Bacteriophage λ : Infection at High Multiplicity	2.42
6	Precipitation of Bacteriophage λ Particles from Large-scale Lysates	2.43
7	Assaying the DNA Content of Bacteriophage λ Stocks and Lysates by Gel Electrophoresis	2.45
8	Purification of Bacteriophage λ Particles by Isopycnic Centrifugation through CsCl Gradients	2.47
	• Alternative Protocol: Purification of Bacteriophage λ Particles by Isopycnic Centrifugation through CsCl Equilibration Gradients	2.51
9	Purification of Bacteriophage λ Particles by Centrifugation through a Glycerol Step Gradient	2.52
10	Purification of Bacteriophage λ Particles by Pelleting/Centrifugation	2.54
11	Extraction of Bacteriophage λ DNA from Large-scale Cultures Using Proteinase K and SDS	2.56
12	Extraction of Bacteriophage λ DNA from Large-scale Cultures Using Formamide	2.59
13	Preparation of Bacteriophage λ DNA Cleaved with a Single Restriction Enzyme for Use as a Cloning Vector	2.61
14	Preparation of Bacteriophage λ DNA Cleaved with Two Restriction Enzymes for Use as a Cloning Vector	2.64
15	Alkaline Phosphatase Treatment of Bacteriophage λ Vector DNA	2.68
16	Purification of Bacteriophage λ Arms: Centrifugation through Sucrose Density Gradients	2.71
17	Partial Digestion of Eukaryotic DNA for Use in Genomic Libraries: Pilot Reactions	2.76
18	Partial Digestion of Eukaryotic DNA for Use in Genomic Libraries: Preparative Reactions	2.80
19	Ligation of Bacteriophage λ Arms to Fragments of Foreign Genomic DNA	2.84
20	Amplification of Genomic Libraries	2.87
21	Transfer of Bacteriophage DNA from Plaques to Filters	2.90
	• Alternative Protocol: Rapid Transfer of Plaques to Filters	2.95
22	Hybridization of Bacteriophage DNA on Filters	2.96
23	Rapid Analysis of Bacteriophage λ Isolates: Purification of λ DNA from Plate Lysates	2.101
	• Additional Protocol: Removing Polysaccharides by Precipitation with CTAB	2.105
24	Rapid Analysis of Bacteriophage λ Isolates: Purification of λ DNA from Liquid Cultures	2.106
INFORMATION PANELS		
	Bacteriophages: Historical Perspective	2.109
	Minimizing Damage to Large DNA Molecules	2.110
	In Vitro Packaging	2.110

*viii Contents***Chapter 3**
Working with Bacteriophage M13 Vectors 3.1**INTRODUCTION****PROTOCOLS**

1	Plating Bacteriophage M13	3.17
2	Growing Bacteriophage M13 in Liquid Culture	3.20
3	Preparation of Double-stranded (Replicative Form) Bacteriophage M13 DNA	3.23
4	Preparation of Single-stranded Bacteriophage M13 DNA	3.26
5	Large-scale Preparation of Single-stranded and Double-stranded Bacteriophage M13 DNA	3.30
6	Cloning into Bacteriophage M13 Vectors	3.33
7	Analysis of Recombinant Bacteriophage M13 Clones	3.39
	• Alternative Protocol: Screening Bacteriophage M13 Plaques by Hybridization	3.41
8	Producing Single-stranded DNA with Phagemid Vectors	3.42

INFORMATION PANELS

Growth Times	3.49
Polyethylene Glycol	3.49

Chapter 4
Working with High-capacity Vectors 4.1**INTRODUCTION****PROTOCOLS**

1	Construction of Genomic DNA Libraries in Cosmid Vectors	4.11
2	Screening an Unamplified Cosmid Library by Hybridization: Plating the Library onto Filters	4.24
	• Additional Protocol: Reducing Cross-hybridization	4.27
3	Amplification and Storage of a Cosmid Library: Amplification in Liquid Culture	4.28
4	Amplification and Storage of a Cosmid Library: Amplification on Filters	4.31
	• Alternative Protocol: Amplification on Plates	4.34
5	Working with Bacteriophage P1 and Its Cloning Systems	4.35
	• Additional Protocol: Purification of High-molecular-weight DNA by Drop Analysis	4.44
	• Alternative Protocol: Purification of High-molecular-weight Circular DNA by Chromatography on Qiagen Resin	4.45
6	Transferring P1 Clones between <i>E. coli</i> Hosts	4.46
7	Working with Bacterial Artificial Chromosomes	4.48
8	Isolation of BAC DNA from Small-scale Cultures	4.53
9	Isolation of BAC DNA from Large-scale Cultures	4.55
10	Working with Yeast Artificial Chromosomes	4.58
11	Growth of <i>S. cerevisiae</i> and Preparation of DNA	4.67
12	Small-scale Preparations of Yeast DNA	4.70
13	Analyzing Yeast Colonies by PCR	4.72

Contents ix

14 Isolating the Ends of Genomic DNA Fragments Cloned in High-capacity Vectors: Vectorette Polymerase Chain Reactions	4.74
--	------

INFORMATION PANELS

Cre-loxP	4.82
Large-fragment Cloning Products and Services	4.86

Chapter 5**Gel Electrophoresis of DNA and Pulsed-field Agarose
Gel Electrophoresis****INTRODUCTION****PROTOCOLS**

1 Agarose Gel Electrophoresis	5.4
2 Detection of DNA in Agarose Gels	5.14
3 Recovery of DNA from Agarose Gels: Electrophoresis onto DEAE-cellulose Membranes	5.18
4 Recovery of DNA from Agarose and Polyacrylamide Gels: Electroelution into Dialysis Bags	5.23
5 Purification of DNA Recovered from Agarose and Polyacrylamide Gels by Anion-exchange Chromatography	5.26
6 Recovery of DNA from Low-melting-temperature Agarose Gels: Organic Extraction • Alternative Protocol: Recovery of DNA from Agarose Gels Using Glass Beads	5.29
7 Recovery of DNA from Low-melting-temperature Agarose Gels: Enzymatic Digestion with Agarase	5.33
8 Alkaline Agarose Gel Electrophoresis • Additional Protocol: Autoradiography of Alkaline Agarose Gels	5.36
9 Neutral Polyacrylamide Gel Electrophoresis	5.40
10 Detection of DNA in Polyacrylamide Gels by Staining	5.47
11 Detection of DNA in Polyacrylamide Gels by Autoradiography	5.49
12 Isolation of DNA Fragments from Polyacrylamide Gels by the Crush and Soak Method	5.51
Introduction to Pulsed-field Gel Electrophoresis (Protocols 13–20)	5.55
13 Preparation of DNA for Pulsed-field Gel Electrophoresis: Isolation of DNA from Mammalian Cells and Tissues	5.61
14 Preparation of DNA for Pulsed-field Gel Electrophoresis: Isolation of Intact DNA from Yeast	5.65
15 Restriction Endonuclease Digestion of DNA in Agarose Plugs	5.68
16 Markers for Pulsed-field Gel Electrophoresis	5.71
17 Pulsed-field Gel Electrophoresis via Transverse Alternating Field Electrophoresis Gels • Alternative Protocol: Silver Staining PFGE Gels	5.74
18 Pulsed-field Gel Electrophoresis via Contour-clamped Homogeneous Electric Field Gels	5.79
19 Direct Retrieval of DNA Fragments from Pulsed-field Gels	5.83
20 Retrieval of DNA Fragments from Pulsed-field Gels following DNA Concentration	5.86

x Contents**Chapter 6****Preparation and Analysis of Eukaryotic Genomic DNA****6.1****INTRODUCTION****PROTOCOLS**

1	Isolation of High-molecular-weight DNA from Mammalian Cells Using Proteinase K and Phenol	6.4
	• Additional Protocol: Estimating the Concentration of DNA by Fluorometry	6.12
2	Isolation of High-molecular-weight DNA from Mammalian Cells Using Formamide	6.13
3	Isolation of DNA from Mammalian Cells by Spooling	6.16
4	Isolation of DNA from Mammalian Cells Grown in 96-well Microtiter Plates	6.19
	• Additional Protocol: Optimizing Genomic DNA Isolation for PCR	6.22
5	Preparation of Genomic DNA from Mouse Tails and Other Small Samples	6.23
	• Alternative Protocol: Isolation of DNA from Mouse Tails without Extraction by Organic Solvents	6.26
	• Alternative Protocol: One-tube Isolation of DNA from Mouse Tails	6.26
	• Alternative Protocol: DNA Extraction from Paraffin Blocks	6.27
6	Rapid Isolation of Mammalian DNA	6.28
7	Rapid Isolation of Yeast DNA	6.31
	Introduction to Southern Hybridization (Protocols 8–10)	6.33
8	Southern Blotting: Capillary Transfer of DNA to Membranes	6.39
9	Southern Blotting: Simultaneous Transfer of DNA from a Single Agarose Gel to Two Membranes	6.47
10	Southern Hybridization of Radiolabeled Probes to Nucleic Acids Immobilized on Membranes	6.50
	• Additional Protocol: Stripping Probes from Membranes	6.57
	• Additional Protocol: Hybridization at Low Stringency	6.58

INFORMATION PANELS

Formamide and Its Uses in Molecular Cloning	6.59
Spooling DNA (Historical Footnote)	6.61
Rapid Hybridization Buffers	6.61
CTAB	6.62

Chapter 7**Extraction, Purification, and Analysis of mRNA from Eukaryotic Cells****7.1****INTRODUCTION****PROTOCOLS**

1	Purification of RNA from Cells and Tissues by Acid Phenol–Guanidinium Thiocyanate–Chloroform Extraction	7.4
2	A Single-step Method for the Simultaneous Preparation of DNA, RNA, and Protein from Cells and Tissues	7.9

Contents xi

3 Selection of Poly(A) ⁺ RNA by Oligo(dT)-Cellulose Chromatography	7.13
4 Selection of Poly(A) ⁺ RNA by Batch Chromatography	7.18
Introduction to Northern Hybridization (Protocols 5–9)	7.21
5 Separation of RNA According to Size: Electrophoresis of Glyoxylated RNA through Agarose Gels	7.27
6 Separation of RNA According to Size: Electrophoresis of RNA through Agarose Gels Containing Formaldehyde	7.31
7 Transfer and Fixation of Denatured RNA to Membranes • Alternative Protocol: Capillary Transfer by Downward Flow	7.35
8 Northern Hybridization	7.42
9 Dot and Slot Hybridization of Purified RNA	7.46
10 Mapping RNA with Nuclease S1	7.51
11 Ribonuclease Protection: Mapping RNA with Ribonuclease and Radiolabeled RNA Probes	7.63
12 Analysis of RNA by Primer Extension	7.75

INFORMATION PANELS

How to Win the Battle with RNase	7.82
Inhibitors of RNases	7.83
Diethylpyrocarbonate	7.84
Guanidinium Salts	7.85
Nuclease S1	7.86
Exonuclease VII	7.86
Mung Bean Nuclease	7.87
Promoter Sequences Recognized by Bacteriophage-encoded RNA Polymerases	7.87
Actinomycin D	7.88

INDEX, I.1**Volume 2**

Chapter 8	
In Vitro Amplification of DNA by the Polymerase Chain Reaction	8.1

INTRODUCTION**PROTOCOLS**

1 The Basic Polymerase Chain Reaction	8.18
2 Purification of PCR Products in Preparation for Cloning	8.25
3 Removal of Oligonucleotides and Excess dNTPs from Amplified DNA by Ultrafiltration	8.27
Introduction to Cloning PCR Products (Protocols 4–7)	8.30
4 Blunt-end Cloning of PCR Products	8.32
5 Cloning PCR Products into T Vectors	8.35
6 Cloning PCR Products by Addition of Restriction Sites to the Termini of Amplified DNA	8.37
7 Genetic Engineering with PCR	8.42
8 Amplification of cDNA Generated by Reverse Transcription of mRNA (RT-PCR)	8.46

xii Contents

9	Rapid Amplification of 5' cDNA Ends (5'-RACE)	8.54
10	Rapid Amplification of 3' cDNA Ends (3'-RACE)	8.61
11	Mixed Oligonucleotide-primed Amplification of cDNA (MOPAC)	8.66
12	Rapid Characterization of DNAs Cloned in Prokaryotic Vectors	8.72
	• Additional Protocol: Screening Yeast Colonies by PCR	8.75
	• Additional Protocol: Screening Bacteriophage λ Libraries	8.76
13	Long PCR	8.77
14	Inverse PCR	8.81
15	Quantitative PCR	8.86
16	Differential Display-PCR (DD-PCR)	8.96
INFORMATION PANELS		
	Multiplex PCR	8.107
	Taq DNA Polymerase	8.108
	Hot Start PCR	8.110
	Ribonuclease H	8.111
	Terminal Transferase	8.111
	Touchdown PCR	8.112
	Use of Inosine in Degenerate Pools of Oligonucleotides Used for PCR	8.113
	Universal Primers	8.113

Chapter 9**Preparation of Radiolabeled DNA and RNA Probes****9.1****INTRODUCTION****PROTOCOLS**

1	Random Priming: Radiolabeling of Purified DNA Fragments by Extension of Random Oligonucleotides	9.4
2	Random Priming: Radiolabeling of DNA by Extension of Random Oligonucleotides in the Presence of Melted Agarose	9.9
	• Nick Translation: An Historical Note	9.12
3	Radiolabeling of DNA Probes by the Polymerase Chain Reaction	9.14
	• Additional Protocol: Asymmetric Probes	9.18
4	Synthesis of Single-stranded DNA Probes of Defined Length from Bacteriophage M13 Templates	9.19
5	Synthesis of Single-stranded DNA Probes of Heterogeneous Length from Bacteriophage M13 Templates	9.25
6	Synthesis of Single-stranded RNA Probes by In Vitro Transcription	9.29
	• Additional Protocol: Using PCR to Add Promoters for Bacteriophage-encoded RNA Polymerases to Fragments of DNA	9.36
7	Synthesis of cDNA Probes from mRNA Using Random Oligonucleotide Primers	9.38
8	Synthesis of Radiolabeled, Subtracted cDNA Probes Using Oligo(dT) as a Primer	9.41
9	Radiolabeling of Subtracted cDNA Probes by Random Oligonucleotide Extension	9.46
10	Labeling 3' Termini of Double-stranded DNA Using the Klenow Fragment of <i>E. coli</i> DNA Polymerase I	9.51
11	Labeling 3' Termini of Double-stranded DNA with Bacteriophage T4 DNA Polymerase	9.57
12	End Labeling Protruding 3' Termini of Double-stranded DNA with [α - 32 P]Cordycepin 5' Triphosphate or [α - 32 P]dideoxy ATP	9.60

Contents **xiii**

13	Dephosphorylation of DNA Fragments with Alkaline Phosphatase	9.62
14	Phosphorylation of DNA Molecules with Protruding 5'-Hydroxyl Termini	9.66
15	Phosphorylation of DNA Molecules with Dephosphorylated Blunt Ends or Recessed 5' Termini	9.70
16	Phosphorylation of DNA Molecules with Protruding 5' Termini by the Exchange Reaction	9.73

INFORMATION PANELS

Nonradioactive Labeling of Nucleic Acids	9.76
<i>E. coli</i> DNA Polymerase I and the Klenow Fragment	9.82
In Vitro Transcription Systems	9.87
Isolating Differentially Expressed cDNAs by Differential Screening and Cloning	9.89
Alkaline Phosphatase	9.92

Chapter 10 **Working with Synthetic Oligonucleotide Probes** **10.1**

INTRODUCTION**PROTOCOLS**

1	Purification of Synthetic Oligonucleotides by Polyacrylamide Gel Electrophoresis	10.11
2	Phosphorylating the 5' Termini of Oligonucleotides	10.17
3	Purification of Radiolabeled Oligonucleotides by Precipitation with Ethanol	10.20
4	Purification of Radiolabeled Oligonucleotides by Precipitation with Cetylpyridinium Bromide	10.22
5	Purification of Radiolabeled Oligonucleotides by Size-exclusion Chromatography	10.25
6	Purification of Radiolabeled Oligonucleotides by Chromatography on a Sep-Pak C ₁₈ Column	10.28
7	Labeling of Synthetic Oligonucleotides Using the Klenow Fragment of <i>E. coli</i> DNA Polymerase I	10.30
8	Hybridization of Oligonucleotide Probes in Aqueous Solutions: Washing in Buffers Containing Quaternary Ammonium Salts	10.35
9	Empirical Measurement of Melting Temperature	10.38

INFORMATION PANELS

Oligonucleotide Synthesis	10.42
Melting Temperatures	10.47
Methods Used to Purify Synthetic Oligonucleotides	10.48

Chapter 11 **Preparation of cDNA Libraries and Gene Identification** **11.1**

INTRODUCTION**PROTOCOLS**

1	Construction of cDNA Libraries	11.38
	Stage 1: Synthesis of First-strand cDNA Catalyzed by Reverse Transcriptase	11.39
	Stage 2: Second-strand Synthesis	11.44

xiv Contents

Stage 3: Methylation of cDNA	11.49
Stage 4: Attachment of Linkers or Adaptors	11.52
Stage 5: Fractionation of cDNA by Gel Filtration through Sepharose CL-4B	11.57
Stage 6: Ligation of cDNA to Bacteriophage λ Arms	11.60
• Alternative Protocol: Ligation of cDNA into a Plasmid Vector	11.64
• Additional Protocol: Amplification of cDNA Libraries	11.65
2 Construction and Screening of Eukaryotic Expression Libraries	11.68
Stage 1: Construction of cDNA Libraries in Eukaryotic Expression Vectors	11.69
Stage 2: Screening cDNA Libraries Constructed in Eukaryotic Expression Vectors	11.75
3 Exon Trapping and Amplification	11.80
Stage 1: Construction of the Library	11.82
Stage 2: Electroporation of the Library into COS-7 Cells	11.87
Stage 3: Harvesting the mRNA	11.89
Stage 4: Reverse Transcriptase-PCR	11.91
Stage 5: Analysis of Clones	11.96
4 Direct Selection of cDNAs with Large Genomic DNA Clones	11.98

INFORMATION PANELS

Commercial Kits for cDNA Synthesis and Library Construction	11.109
Mo-MLV Reverse Transcriptase	11.111
Homopolymeric Tailing	11.112
λ gt10 and λ gt11	11.113
Constructing cDNA Libraries from Small Numbers of Cells	11.114
In Vitro Packaging	11.115
COS Cells	11.116
Biotin	11.117
Magnetic Beads	11.120
Ligation-independent Cloning	11.123

Chapter 12	
DNA Sequencing	12.1

INTRODUCTION**PROTOCOLS**

1 Generation of a Library of Randomly Overlapping DNA Inserts	12.10
• Alternative Protocol: Preparation of Small Numbers of Single-stranded DNA Templates from Bacteriophage M13	12.23
• Additional Protocol: Preparation of Dephosphorylated Blunt-ended Bacteriophage M13 Vector DNA for Shotgun Cloning	12.24
2 Preparing Denatured Templates for Sequencing by Dideoxy-mediated Chain Termination	12.26
• Additional Protocol: Rapid Denaturation of Double-stranded DNA	12.30
• Additional Protocol: Purification of Plasmid DNA from Small-scale Cultures by Precipitation with PEG	12.31
3 Dideoxy-mediated Sequencing Reactions Using Bacteriophage T7 DNA Polymerase (Sequenase)	12.32

Contents xv

4	Dideoxy-mediated Sequencing Reactions Using the Klenow Fragment of <i>E. coli</i> DNA Polymerase I and Single-stranded DNA Templates	12.40
5	Dideoxy-mediated Sequencing of DNA Using Taq DNA Polymerase	12.45
6	Cycle Sequencing: Dideoxy-mediated Sequencing Reactions Using PCR and End-labeled Primers • Additional Protocol: Cycle Sequencing Reactions Using PCR and Internal Labeling with [α - ³² P]dNTPs	12.51
7	Chemical Sequencing • Alternative Protocol: Rapid Maxam-Gilbert Sequencing • Additional Protocol: Preparation of End-labeled DNA for Chemical Sequencing	12.60
8	Preparation of Denaturing Polyacrylamide Gels	12.61
9	Preparation of Denaturing Polyacrylamide Gels Containing Formamide	12.70
10	Preparation of Electrolyte Gradient Gels	12.73
11	Loading and Running DNA-sequencing Gels	12.74
12	Autoradiography and Reading of Sequencing Gels	12.81
		12.83
		12.85
		12.90

INFORMATION PANELS

Automated DNA Sequencing	12.94
Microtiter Plates	12.100
The Klenow Fragment of <i>E. coli</i> DNA Polymerase I	12.101
Preparation of Stock Solutions of Oligonucleotide Primers for DNA Sequencing	12.103
Sequenase	12.104
Conventional Chain-termination Sequencing of PCR-amplified DNA	12.106
Preparation of Stock Solutions of dNTPs and ddNTPs for DNA Sequencing	12.107
Glycerol in DNA Sequencing Reactions	12.108
Compressions in DNA Sequencing Gels	12.109
7-deaza-dGTP	12.111
Dichlorodimethylsilane	12.112
Reading an Autoradiograph	12.113
Electrical Mobility of DNA	12.114

Chapter 13
Mutagenesis

13.1

INTRODUCTION**PROTOCOLS**

1	Preparation of Uracil-containing Single-stranded Bacteriophage M13 DNA	13.11
2	Oligonucleotide-directed Mutagenesis of Single-stranded DNA	13.15
3	In Vitro Mutagenesis Using Double-stranded DNA Templates: Selection of Mutants with <i>Dpn</i> I	13.19
4	Oligonucleotide-directed Mutagenesis by Elimination of a Unique Restriction Site (USE Mutagenesis)	13.26
5	Rapid and Efficient Site-directed Mutagenesis by the Single-tube Megaprimer PCR Method	13.31
6	Site-specific Mutagenesis by Overlap Extension	13.36

xvi Contents

7	Screening Recombinant Clones for Site-directed Mutagenesis by Hybridization to Radiolabeled Oligonucleotides	13.40
•	Alternative Protocol: Screening Phagemid-containing Bacterial Colonies by Hybridization to Radiolabeled Oligonucleotides	13.47
•	Alternative Protocol: Detection of Defined Mutants by PCR	13.48
8	Detection of Mutations by Single-strand Conformational Polymorphism and Heteroduplex Analysis	13.49
9	Generation of Sets of Nested Deletion Mutants with Exonuclease III	13.57
10	Generation of Bidirectional Sets of Deletion Mutants by Digestion with BAL 31 Nuclease	13.62
INFORMATION PANELS		
	BAL 31	13.68
	Exonuclease III	13.72
	Linker-scanning Mutagenesis	13.75
	Random Mutagenesis	13.78
	Alanine-scanning Mutagenesis	13.81
	Mutagenic Oligonucleotides	13.82
	Selecting against Wild-type DNA in Site-directed Mutagenesis	13.84
	<i>N</i> ⁶ -methyladenine, Dam Methylase, and Methylation-sensitive Restriction Enzymes	13.87
	Commercial Kits for Site-directed Mutagenesis	13.89
	Glycerol	13.90
	Mutation Detection	13.91

Chapter 14**Screening Expression Libraries****14.1****INTRODUCTION****PROTOCOLS**

1	Screening Expression Libraries Constructed in Bacteriophage λ Vectors	14.4
2	Screening Expression Libraries Constructed in Plasmid Vectors	14.14
3	Removal of Cross-reactive Antibodies from Antiserum: Pseudoscreening	14.23
•	Alternative Protocol: Adsorbing Antibodies with Lysates of Bacteriophage-infected Cells	14.25
4	Removal of Cross-reactive Antibodies from Antiserum: Incubation with <i>E. coli</i> Lysate	14.26
5	Removal of Cross-reactive Antibodies from Antiserum: Affinity Chromatography	14.28
6	Identifying DNA-binding Proteins in Bacteriophage λ Expression Libraries	14.31
7	Preparation of Lysates Containing Fusion Proteins Encoded by Bacteriophage λ: Lysis of Bacterial Colonies	14.37
8	Preparation of Lysates Containing Fusion Proteins Encoded by Bacteriophage λ: Lytic Infections on Agar Plates	14.41
9	Preparation of Lysates Containing Fusion Proteins Encoded by Bacteriophage λ: Lytic Infections in Liquid Medium	14.44

INFORMATION PANELS

Plasmid and Bacteriophage λ Expression Vectors	14.47
Using Antibodies in Immunological Screening	14.50

INDEX, I.1

Volume 3

Chapter 15

Expression of Cloned Genes in *Escherichia coli*

15.1

INTRODUCTION

PROTOCOLS

1 Expression of Cloned Genes in <i>E. coli</i> Using IPTG-inducible Promoters	15.14
2 Expression of Cloned Genes in <i>E. coli</i> Using the Bacteriophage T7 Promoter	15.20
3 Expression of Cloned Genes in <i>E. coli</i> Using the Bacteriophage λ ρ_L Promoter	15.25
4 Expression of Secreted Foreign Proteins Using the Alkaline Phosphatase Promoter (<i>phoA</i>) and Signal Sequence	15.30
• Additional Protocol: Subcellular Localization of PhoA Fusion Proteins	15.35
5 Purification of Fusion Proteins by Affinity Chromatography on Glutathione Agarose	15.36
6 Purification of Maltose-binding Fusion Proteins by Affinity Chromatography on Amylose Resin	15.40
7 Purification of Histidine-tagged Proteins by Immobilized Ni^{2+} Absorption Chromatography	15.44
• Alternative Protocol: Elution of Polyhistidine-tagged Proteins from Metal Affinity Columns Using Decreasing pH	15.47
• Additional Protocol: Regeneration of NTA- Ni^{2+} -Agarose	15.48
8 Purification of Expressed Proteins from Inclusion Bodies	15.49
• Additional Protocol: Refolding Solubilized Proteins Recovered from Inclusion Bodies	15.53

INFORMATION PANELS

Expression of Cloned Genes	15.55
<i>E. coli</i> Expression Systems	15.56
LacZ Fusions	15.57
Chaotropic Agents	15.60

Chapter 16

Introducing Cloned Genes into Cultured Mammalian Cells

16.1

INTRODUCTION

PROTOCOLS

1 DNA Transfection Mediated by Lipofection	16.7
• Additional Protocol: Histochemical Staining of Cell Monolayers for β -Galactosidase	16.13
2 Calcium-phosphate-mediated Transfection of Eukaryotic Cells with Plasmid DNAs	16.14
• Alternative Protocol: High-efficiency Calcium-phosphate-mediated Transfection of Eukaryotic Cells with Plasmid DNAs	16.19
3 Calcium-phosphate-mediated Transfection of Cells with High-molecular-weight Genomic DNA	16.21

xviii Contents

• Alternative Protocol: Calcium-phosphate-mediated Transfection of Adherent Cells	16.25
• Alternative Protocol: Calcium-phosphate-mediated Transfection of Cells Growing in Suspension	16.26
4 Transfection Mediated by DEAE-Dextran: High-efficiency Method	16.27
• Alternative Protocol: Transfection Mediated by DEAE-Dextran: Increased Cell Viability	16.32
5 DNA Transfection by Electroporation	16.33
6 DNA Transfection by Biolistics	16.37
• Additional Protocol: Histochemical Staining of Cell Monolayers or Tissue for β -Glucuronidase	16.42
7 DNA Transfection Using Polybrene	16.43

INFORMATION PANELS

Cotransformation	16.47
Selective Agents for Stable Transformation	16.48
Lipofection	16.50
Transfection of Mammalian Cells with Calcium Phosphate-DNA Coprecipitates	16.52
Chloroquine Diphosphate	16.53
Electroporation	16.54

Chapter 17**Analysis of Gene Expression in Cultured Mammalian Cells****17.1****INTRODUCTION****PROTOCOLS*****Cis*-acting Regions and *Trans*-acting Factors**

1 Mapping Protein-binding Sites on DNA by DNase I Footprinting	17.4
• Alternative Protocol: Mapping Protein-binding Sites on DNA by Hydroxyl Radical Footprinting	17.12
2 Gel Retardation Assays for DNA-binding Proteins	17.13
• Additional Protocol: Supershift Assays	17.17
• Additional Protocol: Competition Assays	17.17
3 Mapping DNase-I-hypersensitive Sites	17.18

Analysis of Primary Transcripts

4 Transcriptional Run-on Assays	17.23
--	-------

Reporter Assays

Introduction to Reporter Assays: CAT, Luciferase, and β-galactosidase (Protocols 5–7)	17.30
5 Measurement of Chloramphenicol Acetyltransferase in Extracts of Mammalian Cells Using Thin-layer Chromatography	17.33
• Alternative Protocol: Measurement of CAT by Extraction with Organic Solvents	17.40
• Alternative Protocol: Measurement of CAT following Diffusion of Reaction Products into Scintillation Fluid	17.41
6 Assay for Luciferase in Extracts of Mammalian Cells	17.42

Contents *xix*

• Alternative Protocol: Using a Scintillation Counter to Measure Luciferase	17.46
• Alternative Protocol: Assay for Luciferase in Cells Growing in 96-well Plates	17.47
7 Assay for β-galactosidase in Extracts of Mammalian Cells	17.48
Inducible Systems	
8 Tetracycline as Regulator of Inducible Gene Expression in Mammalian Cells	17.52
Stage 1: Stable Transfection of Fibroblasts with pTet-tTAk	17.60
Stage 2: Stable Transfection of Inducible tTA-expressing NIH-3T3 Cells with Tetracycline-regulated Target Genes	17.65
Stage 3: Analysis of Protein Expression in Transfected Cells	17.68
• Alternative Protocol: Tetracycline-regulated Induction of Gene Expression in Transiently Transfected Cells Using the Autoregulatory tTA System	17.70
9 Ecdysone as Regulator of Inducible Gene Expression in Mammalian Cells	17.71

INFORMATION PANELS

Footprinting DNA	17.75
Gel Retardation Assays	17.78
Baculoviruses and Baculovirus Expression Systems	17.81
Green Fluorescent Proteins	17.84
Epitope Tagging	17.90
Chloramphenicol Acetyltransferase	17.94
Luciferase	17.96
β -galactosidase	17.97

Chapter 18**Protein Interaction Technologies**

18.1

INTRODUCTION**PROTOCOLS**

1 Two-hybrid and Other Two-component Systems	18.6
Stage 1: Characterization of a Bait-LexA Fusion Protein	18.17
• Alternative Protocol: Assay of β -galactosidase Activity by Chloroform Overlay	18.28
Stage 2: Selecting an Interactor	18.30
Stage 3: Second Confirmation of Positive Interactions	18.38
• Alternative Protocol: Rapid Screen for Interaction Trap Positives	18.46
2 Detection of Protein-Protein Interactions Using Far Western with GST Fusion Proteins	18.48
• Additional Protocol: Refolding of Membrane-bound Proteins	18.53
• Alternative Protocol: Detection of Protein-Protein Interactions with Anti-GST Antibodies	18.54
3 Detection of Protein-Protein Interactions Using the GST Fusion Protein Pulldown Technique	18.55
4 Identification of Associated Proteins by Coimmunoprecipitation	18.60
5 Probing Protein Interactions Using GFP and Fluorescence Resonance Energy Transfer	18.69
Stage 1: Labeling Proteins with Fluorescent Dyes	18.80

xx Contents

Stage 2: Cell Preparation for FLIM-FRET Analysis	18.84
• Alternative Protocol: Preparation of Fixed Cells for FLIM-FRET Analysis	18.87
• Alternative Protocol: Microinjection of Live Cells	18.88
Stage 3: FLIM-FRET Measurements	18.90
6 Analysis of Interacting Proteins with Surface Plasmon Resonance Spectroscopy Using BIAcore	18.96
Stage 1: Preparation of the Capture Surface and Test Binding	18.104
Stage 2: Kinetic Analysis of the Antibody-Antigen Interaction	18.108

INFORMATION PANELS

Filamentous Phage Display	18.115
Genomics and the Interaction Trap	18.123
Interaction Trap and Related Technologies	18.125

Appendices

1 Preparation of Reagents and Buffers Used in Molecular Cloning, A1.1
2 Media, A2.1
3 Vectors and Bacterial Strains, A3.1
4 Enzymes Used in Molecular Cloning, A4.1
5 Inhibitors of Enzymes, A5.1
6 Nucleic Acids, A6.1
7 Codons and Amino Acids, A7.1
8 Commonly Used Techniques in Molecular Cloning, A8.1
9 Detection Systems, A9.1
10 DNA Array Technology, A10.1
11 Bioinformatics, A11.1
12 Cautions, A12.1
13 Suppliers, A13.1
14 Trademarks, A14.1
Appendix References, R1

INDEX, I.1